The Pennant Group, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US70805E1091
USD
28.94
-0.33 (-1.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About The Pennant Group, Inc. stock-summary
stock-summary
The Pennant Group, Inc.
Pharmaceuticals & Biotechnology
Pennant Group, Inc. is a holding company. The Company through its subsidiaries provides healthcare services to the senior population in the United States. The Company operates home health, hospice and senior living across Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. It operates through two segments: home health and hospice services and senior living services. It's home health and hospice services segment include its home health, hospice and home care businesses. It provides home health and hospice services through approximately 80 agencies. Senior living services segment includes its assisted living, independent living and memory care communities. It provides assisted living, independent living and memory care services at approximately 54 communities with 3,872 total units.
Company Coordinates stock-summary
Company Details
1675 E Riverside Dr Ste 150 , EAGLE ID : 83616-7471
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 54 Schemes (37.94%)

Foreign Institutions

Held by 89 Foreign Institutions (18.9%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Daniel Walker
Chairman of the Board, Chief Executive Officer
Mr. Christopher Christensen
Director
Mr. Stephen Covey
Independent Director
Mr. Scott Lamb
Independent Director
Mr. Roderic Lewis
Independent Director
Dr. John Nackel
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
220 Million
(Quarterly Results - Jun 2025)
Net Profit:
8 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 847 Million (Small Cap)

stock-summary
P/E

35.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

10.02%

stock-summary
Price to Book

2.70